Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) Introduces New Oncology Molecule with Activity in Broad Range of Cancer Models

CHICAGO, June 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today presented results of research on a new oncology molecule, MLN4924, a first-in-class, small molecule inhibitor of the Nedd 8 Activating Enzyme (NAE). NAE is a novel Millennium-discovered target in the protein homeostasis pathway. NAE acts upstream of the proteasome, the target of VELCADE(R) (bortezomib) for Injection, the Company's market-leading therapy for patients with previously treated multiple myeloma and mantle cell lymphoma. The data on NAE were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

(LOGO: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"Millennium is a leader in protein homeostasis research, and our discoveries of NAE and MLN4924 demonstrate our strength and innovation in this unique area," said Joe Bolen, Ph.D., Chief Scientific Officer, Millennium. "Building on the clinical and commercial success of VELCADE, we believe that MLN4924 has the potential to deliver enhanced efficacy with an improved safety profile in a broad range of solid and hematological tumors. The preclinical work conducted to date has shown that MLN4924 has substantial and durable anti-tumor activity."

Data presented by Mark Rolfe, Ph.D., Vice President, Millennium Oncology Discovery, showed:

-- NAE is a novel target in the protein homeostasis pathway that specifically controls a subset of proteins which regulates survival of cancer cells -- NAE has been validated as an oncology target in hematological and solid tumors - Molecular pathology studies have shown elevated NAE expression in primary human tumors including colon, lung and ovarian as well as colon metastasis to the liver - Conversely, NAE expression is low in normal human tissues -- MLN4924 has shown substantial activity in a broad range of preclinical solid and hematological tumor models

The Company is currently conducting investigational new drug (IND) enabling work for MLN4924 and expects to enter human clinical trials with the molecule in advanced cancer patients in 2008.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty percent of patients reported serious adverse events. The most commonly reported serious adverse events were pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

Contacts: Jennifer Snyder (media) Kyle Kuvalanka (investors) (617) 448-0281 (857) 498-0818

Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.

CONTACT: Media, Jennifer Snyder, +1-617-448-0281, or Investors, KyleKuvalanka, +1-857-498-0818, for Millennium Pharmaceuticals, Inc.

Back to news